Kaken Pharmaceutical Co Ltd 2020 Integrated Report
The report covers April 2019-March 2020 and highlights consolidated net sales of ¥89,232 million alongside 1,268 consolidated employees. It describes five priority issues spanning medical responsibility, governance, the environment and fulfilling workplaces, selected through business-relevance and stakeholder-impact mapping. Environmental disclosures include FY2019 CO2 emissions of 21,279 t-CO2 and waste produced of 618 tons at the Shizuoka site and Kyoto Drug Research Center. The company also reports appointing a female outside director and continuing employee health, safety and training initiatives.
Company: Kaken Pharmaceutical Co Ltd
Sector: Manufacturing
Country: Japan
Year: 2020
Type: Integrated Report
Pages: 82
Back to company
Kaken Pharmaceutical Co Ltd
Corporate Report
The report covers April 2019-March 2020 and highlights consolidated net sales of ¥89,232 million alongside 1,268 consolidated employees. It describes five priority issues spanning medical responsibility, governance, the environment and fulfilling workplaces, selected through business-relevance and stakeholder-impact mapping. Environmental disclosures include FY2019 CO2 emissions of 21,279 t-CO2 and waste produced of 618 tons at the Shizuoka site and Kyoto Drug Research Center. The company also reports appointing a female outside director and continuing employee health, safety and training initiatives.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2020
Reporting Period
Apr 1, 2019 - Mar 31, 2020
Fiscal Year
2020
Type
Integrated Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Water Consumption
Total Waste
Women on Board
Employees